[Article title missing]

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, but its treatment is challenging, which may be due to lack of focus. Recent years have seen considerable developments in biotargeted therapies targeting two important pathophysiologic mechanisms for treating GIOP, including increased osteoclast activities induced by receptor activator of nuclear factor-κB ligand and decreased bone formation induced by inhibition of Wnt signaling pathway. We summarized the latest advances in three biotargeted drugs, denosumab, sclerostin monoclonal antibody and DKK-1 monoclonal antibody, in the treatment of GIOP, and found that denosumab can significantly increase bone mineral density of patients with GIOP, and sclerostin monoclonal antibody and DKK-1 monoclonal antibody are new promising therapies for GIOP. However, due to limited evidence, efficacies of these biotargeted drugs in GIOP need to be studied further.

Keywords

• |osteoporosis|glucocorticoid-induced osteoporosis|denosumab|sclerostin|dickkopf-1|monocolonal antibody